Although frequentist approaches to prevalence estimation are simple to apply, there are circumstances where it is difficult to satisfy assumptions of asymptotic normality and nonsensical point estimates (greater than 1 or less than 0) may result. This is particularly true when sample sizes are small, test prevalences are low and imperfect sensitivity and specificity of diagnostic tests need to be incorporated into calculations of true prevalence. Bayesian approaches offer several advantages including direct computation of rangerespecting interval estimates (e.g. intervals between 0 and 1 for prevalence) without the requirement of transformations or large-sample approximations. They also allow direct probabilistic interpretation, and the flexibility to model in a straightforward manner the probability of zero prevalence. In this review, we present frequentist and Bayesian methods for animal-and herd-level true prevalence estimation based on individual and pooled samples. We provide statistical methods for detecting differences between population prevalence and frequentist methods for sample size and power calculations. All examples are motivated using Mycobacterium avium subspecies paratuberculosis infection and we provide WinBUGS code for all examples of Bayesian estimation.
Introduction
Prevalence is a measure of disease frequency that focuses on existing status rather than new events (Rothman and Greenland, 1998) . Though incidence is of primary importance in etiological research, prevalence is often used in the study of chronic diseases of insidious onset (e.g. Johne's disease) where incident cases are difficult to define even if populations are monitored longitudinally.
Diagnostic tests are commonly used for prevalence surveys and, ideally, true prevalence should be estimated from apparent (test) prevalence by adjusting for test sensitivity (Se) and specificity (Sp) . Lack of knowledge of or disregard for test errors (false positives and negatives) can lead to inaccurate sample size calculations for surveys, misclassification of diseased and non-diseased states, and biased estimates of measures of effect in risk factor studies. All of these negatively impact disease *Corresponding author. E-mail: iagardner@ucdavis.edu surveillance, control and eradication programs and, consequently, animal trade.
Frequentist methods have traditionally been used for animal-health prevalence surveys. In recent years, however, applications of Bayesian analytic methods for veterinary epidemiologic data have increased (Cowling et al., 1999; Staubach et al., 2002; Clough et al., 2003; van Schaik et al., 2003; Borel et al., 2004; Branscum et al., 2004; Dorny et al., 2004; Geurden et al., 2004; Ngowi et al., 2004; Carabin et al., 2005; Durr et al., 2005; Benito et al., 2006; Rapsch et al., 2006; Wang et al., 2006) . Bayesian statistical analysis of prevalence data is appealing because it formally incorporates previously-collected prevalence data and expert-elicited information into current calculations (Gardner, 2002) . In addition, when sample sizes for prevalence surveys are small, prevalence is low and results are based on imperfect diagnostic tests, it may be difficult to satisfy large-sample normal approximations when frequentist confidence intervals (CIs) are constructed. In these circumstances, use of Bayesian methods provides a practical alternative for data analysis.
In this review, we present Bayesian and frequentist approaches to prevalence estimation with examples involving Johne's disease. We highlight advantages and limitations of both approaches while presenting methods for the statistical analysis of individual-level, herd-level and pooled-sample prevalence data as well as review calculations involving prevalence estimates. We conclude with a brief summary of frequentist methods for sample size and power calculations motivated by practical examples. Although we focus on Mycobacterium avium subspecies paratuberculosis (MAP) infection, the issues and methods discussed are broadly applicable to chronic infectious diseases. We note that prevalence also can be estimated from latent class models, e.g. a two-tests in twopopulations design, used primarily for evaluation of test accuracy. For brevity, we do not describe this approach and we refer interested readers to other papers (Hui and Walter, 1980; Johnson et al., 2001; Branscum et al., 2005a) .
Background

Prevalence definitions
Prevalence is a dimensionless, unit-free value ranging from zero to one (zero to 100 if expressed as a percentage). Depending on the context, an investigator might be interested in prevalence of infection, infectious animals or disease. We restrict our presentation to infection prevalence.
Two types of prevalence are usually estimated in epidemiologic studies: point and period prevalence. Point prevalence is the proportion of infected individuals in a defined population (or more generally that have a condition of interest) at a given point in time; hence: Point prevalence=Number of infected individuals= Total number of individuals at risk for infection in the population:
Period prevalence is the proportion of infected individuals in a defined population found over a specified time period (e.g. 2 years). For non-resolvable infections, e.g. MAP infection, point prevalence provides valid estimates of the frequency of individuals that have ever been infected and thus we do not further consider period prevalence in this paper.
Sampling
To justify descriptive inferences and probabilistic interpretations of prevalence estimates based on sample data, random selection of units from the population to be tested is necessary (Greenland, 1990; Greiner and Gardner, 2000a) . Depending on the goals of the survey, availability of resources and logistics, units may be enrolled using simple random, stratified random, systematic random, single or two-stage cluster sampling schemes (Scheaffer et al., 1995) , among other random sampling schemes.
Statistical inference
A frequentist approach assumes the prevalence of the infection (P) in the target population to be a fixed, unknown quantity. Frequentist inferences for P are summarized using a point estimate (P) along with a 100(1Àa)% CI that quantifies inferential precision, where typically a = 0.05. One interpretation of a 100(1Àa)% CI in this context is as follows: if sampling from the source population were repeated to generate all possible samples from the population of a given size without varying the sampling procedure, 100(1Àa)% of the CIs so generated would be expected to contain P. A Bayesian approach assumes a probability distribution for P which characterizes the researcher's uncertainty about the population prevalence independently of the current survey data. Subjective knowledge about P and about test accuracy parameters (i.e. Se and Sp) is elicited from experts familiar with the subject matter or derived from historical or current data obtained from similar populations. This information is formally incorporated into the analysis in the form of probability distributions called prior distributions or, simply, priors. Inferences for P are made by using a likelihood function and the prior distribution to combine information from the data with information independent of the data, respectively, to form the posterior distribution of P. The relationship between the likelihood, prior and posterior is given by: Pr(qjData) |fflfflfflfflfflffl ffl{zfflfflfflfflfflffl ffl} 
where Pr(Á) denotes a probability density or mass function, q denotes parameters in the statistical model and K is a normalizing constant. Summary measures of posterior distributions, such as means or medians, and outer percentiles, form the basis for inference about P. Typically, results are presented in the form of the median and a 100(1Àa)% probability interval (PI) (usually a = 0.05), which provides a range of values that contains P with probability = 1Àa, given the data and model. Hence, unlike CIs, PIs have probabilistic interpretations dependent only on currently observed data and a given set of priors. This renders interpretation and application of results more straightforward for both scientists and policymakers. For further explanation of fundamental concepts of Bayesian inference, we refer the reader to other introductory works (Berry, 1996; Bland and Altman, 1998; Dunson, 2001) . All Bayesian computations presented in this paper were performed using the freely-available WinBUGS software (downloadable from http://www. mrc-bsu.cam.ac.uk/bugs/winbugs/contents.shtml).
3. Individual-level prevalence estimation from individual samples 3.1. Apparent prevalence 3.1.1. Frequentist approach Apparent prevalence (P A ) is the probability that a randomly-chosen unit of observation will test positive (Greiner and Gardner, 2000b) and therefore is dependent on the true population within-herd prevalence (P T ) and Se and Sp of the diagnostic test used. A point estimate of P A based on test outcomes of n randomly sampled individuals from the source population of size N is given bŷ
where x denotes the number of sampled units that test positive. An approximate 100(1Àa)% CI for P A is given by the Wald CI:P
where z a/2 is the 1Àa/2 percentile of the standard normal distribution. Equation (3) is derived assuming (i) x $ bin(n, P A ) and (ii) that this binomial distribution is well approximated by x $ N(nP A , nP A (1ÀP A )). It is usually recommended that both nP A and n(1ÀP A ) be sufficiently large e.g. both greater than 5 (Agresti, 1996, Leemis and Trivedi, 1996) , for the approximation to be valid. Others have suggested that the normal approximation is appropriate for 95 and 99% CIs if 0 <P A AE k ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi f P A (1ÀP A )=n q < 1 for k = 3 and 5, respectively (Enoe et al., 2000) . Key limitations of Wald CIs for P A are that they can provide coverage much less than the nominal level (Agresti and Coull, 1998) , may have lower and upper bounds < 0 and > 1, respectively, and are inappropriate when no animals test positive. Alternative methods for CI calculation exist and here we highlight three common approaches. First, exact CIs can be calculated either from the binomial distribution (see Appendix A.1 for details) or directly from the F distribution using the following formula (Lui, 2004) :
where Q 1 = F 2nÀ2x + 2,2x,1Àa/2 and Q 2 =F 2x+2,2nÀ2x,1Àa=2 Á F df 1 ,df 2 ,1Àa=2 denotes the 100(1Àa/2) percentile of the F distribution with df 1 and df 2 degrees of freedom. For x =0 the lower limit of (4) is defined as 0 and for x = n the upper limit is defined as 1. Second, Agresti and Coull (1998) have shown that the score CI
provides coverage closer to the nominal level than both the Wald and exact CIs for small sample sizes (i.e. 5-100). Third, to circumvent Wald and exact CI coverage limitations, as well as the cumbersomeness of (5), Agresti and Coull (1998) suggest a modified 95% Wald interval (the 'add 2 successes and 2 failures' adjusted Wald interval):P A AE 1:96
whereP A =(x+2)=(n+4). This interval is slightly conservative relative to the score interval but does not suffer from low coverage near 0 and 1 (for sample sizes ranging from 0 to 100) and is still closer to 95% coverage than exact intervals (Agresti and Coull, 1998) .
3.1.1.1. Example Assume that from a very large herd of dairy cows, n = 200 animals are randomly sampled and x = 26 animals test positive for MAP infection, yielding an apparent prevalence estimate of P A = 0.13. Using (3), a 95% CI for P A is 0.083-0.177. Exact calculations using either the binomial or F distributions yield a 95% CI from 0.087 to 0.185, while the 95% score CI is from 0.090 to 0.184. The adjusted Wald 95% CI is from 0.090 to 0.185. If a 100(1Àa)% CI is desired when there are no positive test results, an exact CI can readily be calculated using (0, 1Àa 1/n ) (Louis, 1981) . When n ! 20 and a = 0.05, a good approximation to this interval is 'the rule of three' 95% CI = (0, 3/n) ( Jovanovic and Levy, 1997) . If in our last example, 0 of 200 animals test positive, then using (0, 1Àa 1/n ), a 95% CI for P A is 0-0.0149 and using the 'rule of three' is 0-0.0150. Hence for this scenario, both these methods give practically the same results.
Bayesian approach
Here, the data are supplemented with prior information. Priors for P require distributions ranging from 0 to 1. The beta family provides a class of distributions supported on the unit interval (0-1) with a range of flexible shapes, including U-, J-and L-shaped, unimodal symmetric, right and left skewed and uniform distributions. With a binomial (n, P) likelihood, a beta(a, b) prior for P results in a beta(x + a, n + bÀx) posterior for P. We can summarize posterior inference for P using either the mean or the median and 95% PI of this beta distribution.
To specify values for the hyperparameters a and b for a beta(a, b) prior, we generally use historical data and/ or expert opinion. For instance, to incorporate expert opinion for apparent prevalence, we elicit what the expert believes to be the most likely value of P A in the herd. This serves as a prior point estimate, namely the prior mode of P A . Then, with a specified high probability (usually 0.95 or 0.99), the expert provides a value that P A is believed to be greater than (less than) if the prior mode is greater than (less than) 0.5. The prior mode and outer percentile (95th or 99th) are input into software programs, e.g. BetaBuster (which is downloadable from http://www.epi.ucdavis.edu/diagnostictests/betabuster. html) and the values a and b are produced as output. When little is known of the prior testing history of the herd, a diffuse prior may be used which prescribes equal likelihood to every possible value of the prevalence. A beta(1, 1) (equivalent to a uniform(0, 1)) distribution is an example of one such prior.
Example
Assume that prior to data collection we have no prior information on disease prevalence in the herd sampled in 3.1.1.1. Since the ratio of sample size to herd size (i.e. sample size (n)/herd size (N)) 0.1, we assume a binomial distribution (x $ bin(n, P A )) for the number of animals testing positive (Berry and Lindgren, 1996) . For simplicity, we also assume that Se = Sp = 1 (i.e. P A = P T ). The apparent prevalence can easily be estimated in WinBUGS (see Appendix B.1a). Using a beta(1, 1) prior, the posterior median and 95% PI for P A were 0.132 and 0.090-0.184, respectively. Thus, we are 95% certain that the apparent prevalence is between 0.090 and 0.184. If prior information were available on the prevalence of MAP infection in the herd, this could easily be incorporated into the Bayesian analysis. For example if prior to data collection, the herd veterinarian indicates that, based on a previous survey, he expects that 1 in 10 cows will be seropositive for MAP (mode = 0.1) and he is 95% sure that P A < 0.2. Inputting this information into BetaBuster, we get a beta (5.62, 42.57) prior. This beta prior has a median of 0.111 and 95% PI from 0.043 to 0.220. From WinBUGS (see Appendix B.1b) the posterior median and 95% PI for P A are 0.126 and 0.089-0.171, respectively. Note that the posterior point estimate (0.126) is intermediate between the median of the prior distribution (0.111) and the point estimate obtained from the data (0.130). In addition, we note (as is generally the case) that the posterior interval estimate (95% PI: 0.089-0.171) is narrower than the prior interval estimate (95% PI: 0.043-0.220).
Diagnostic tests
Diagnostic tests commonly used in prevalence studies of Johne's disease in live animals are based on either the identification of the etiologic agent (MAP) or detection of a serum or milk antibody response to its presence (Manning and Collins, 2001; Collins et al., 2006) . Researchers typically use fecal culture as a reference MAP-detection test against which to evaluate the performance of serological tests such as the enzyme-linked immunosorbent assay (ELISA) (Manning and Collins, 2001 ). However, the intermittent fecal shedding of MAP particularly during sub-clinical infection, coupled with late-stage antibody production, makes accurate and precise estimation of test characteristics challenging. Consequently, prevalence estimation methods that rely on these tests should incorporate uncertainty in values of test accuracy parameters such as Se and Sp. Priors for diagnostic tests can be derived based on the results of recent validation studies involving animals with similar characteristics to the ones about to be tested. If during a validation study for test Se, x out of n infected animals test positive for MAP, then a beta(x +1, nÀx + 1) is an appropriate choice of prior for Se (Vose, 2000) . This beta distribution is obtained as the posterior of Se when the validation study data are modeled as bin(n, Se) with a uniform (0, 1) prior on Se. For example, if in a recent validation study, 30 of 100 infected cows tested positive for MAP infection, then a beta(31, 71) prior for Se can be used in analysis of the future prevalence survey data. For our examples, we use two commonlyused diagnostic tests, serum (IDEXX) ELISA and fecal culture on Herrold's egg yolk (HEY) medium. Priors for these tests (see Table 1 ) are based on both the results of validation studies (Sockett et al., 1992; Collins et al., 2005) and expert opinion.
True prevalence
Frequentist approach
True prevalence (P T ) of infection is the probability that a randomly-chosen unit from the source population is infected. Apparent prevalence is related to P T , Se and Sp through the equation P A = P T Se +(1ÀP T )(1ÀSp). Among the first estimators of P T was the Rogan-Gladen-estimator (Rogan and Gladen, 1978) , which is obtained by substitution of estimates of P A , Se and Sp into this equation to yieldP
If Se and Sp are assumed known with certainty, then the standard error of P T is given by: (Greiner and Gardner, 2000a) S:E:
where J = Se + SpÀ1 denotes the Youden index (Youden, 1950) , a combined measure of test accuracy. In practice, Se and Sp are not known with certainty (Greiner and Gardner, 2000a) in which case (Greiner and Gardner, 2000a ) provides a more valid quantification of uncertainty. Here,
where n 1 and n 2 are the numbers of infected and noninfected animals, respectively, in the original test validation study.
3.3.1.1. Example Assume that a serum ELISA (Se = 0.30, Sp = 0.96) was used to test the herd described in section 3.1.1. Then P T = 0.346. If we assume that Se and Sp are known with certainty, then using (8), a 95% CI is 0.167-0.525. Using (9) with n 1 and n 2 = 415 and 359, respectively (Collins et al., 2005) , a more realistic 95% CI that captures the uncertainty in Se and Sp is 0.160-0.533. As is evident from this example, the discrepancy between P T (0.346) and P A (0.13) can be substantial. In general, the more accurate the test, i.e. the closer the Youden index is to 1, the smaller the discrepancy. Though most often P T > P A for a given herd and diagnostic test, the converse is also possible. Using a test with Se = 0.30 and Sp = 0.96, we note that P T < P A when P T < 0.057. Comparing the CIs obtained using formulas (3), (8) and (9), we also note that precision is greater when P A is estimated or when P T is estimated assuming that the diagnostic test's characteristics are known perfectly. In general, while differences between the precision of estimates obtained assuming known and unknown test characteristics are smaller for larger sample sizes (n 1 and n 2 ) of the validation studies originally used to estimate Se and Sp, the difference in bias increases since the bias in P T decreases but not in P A (Rogan and Gladen, 1978) . The application of the Rogan-Gladen-estimator is problematic in some situations because P T can be < 0 or > 1. In the context of MAP infection, only the former is of practical importance and can occur in a small sample with low infection prevalence when the proportion of false-positive results is greater than the apparent prevalence. The limitations of (7) are further exacerbated by the fact that when sample sizes are small and true prevalence low, the normal approximation used for calculation of CIs may not be justifiable. In particular, the condition 0 < P T ± 3S.E.(P T ) < 1 becomes difficult to satisfy when (9) is used. For these reasons, we advise against using (7) for small samples and when prevalence is believed to be close to 0.
Bayesian approach
A Bayesian analysis naturally accounts for uncertainty in the values of P T , Se and Sp. Under binomial sampling, the distribution of the number of animals testing positive is given by xj(P T , Se, Sp) $ bin(n, P A ), where P A = P T Se + (1ÀP T )(1ÀSp). Implicit in the use of a beta prior for the prevalence is the certainty that P T Þ 0. If we wish to allow for the possibility of zero infection prevalence, then we can use the mixture prior distribution: P T $ beta(a, b) with probability = l and P T = 0 with probability = 1Àl. The parameter l denotes the probability that the herd is infected, and in the single herd setting is typically set equal to an expert-specified value, but can alternatively be modeled using a beta distribution (Branscum et al., 2004) . A mixture prior gives a more appropriate statistical model for low prevalence or disease freedom surveys. Models that do not allow for zero prevalence will tend to produce estimates that are biased upwards. As previously mentioned, in addition to modeling P T , beta distributions are commonly used as priors for Se and Sp (see Table 1 ) (Hanson et al., 2003b; Branscum et al., 2004) . For most of the Bayesian examples in this paper, we use data collected from randomly-selected cows in 29 California dairy herds that were tested for Johne's disease using serum (IDEXX) ELISA and/or fecal culture on HEY medium.
Example
Assume that n = 60 cows are randomly selected out of a herd of size 675 and suppose x = 2 cows (3.3%) test positive for MAP infection using a serum ELISA. Note that here the Rogan-Gladen-estimator yields a negative prevalence estimate (P T = À0.026). Since 60/675 = 0.089 < 0.10, the assumption of binomial sampling is reasonable. The probability that the herd is infected was set at l = 0.9 since 90% of herds in California were presumed infected with MAP at the time of sampling. Since no records were available from the herd regarding previous monitoring or diagnostic testing, we assume that, conditional on the herd being MAP-infected, all prevalences are a priori equally likely. This translates to P T $ beta(1, 1) prior distribution. Using beta priors for ELISA Se and Sp (see Table 1 ), the model was fit in WinBUGS (code in Appendix B.2). The estimated (posterior median) prevalence of MAP infection in the herd was 0.02 with 95% PI from 0 to 0.453. Thus, given that 2 animals out of 60 tested positive using ELISA, we are 97.5% certain that P T < 0.453. The analysis also permits inferences regarding the posterior probability that the herd was infected. Given that 2 of 60 animals tested positive, we are 57% sure that the herd was infected. A Bayesian approach is readily implemented for all realizations of x, including x = 0 and x = n. For instance, if no animals had tested positive out of 60, the posterior median and 95% PI would be P T = 0 (95% PI: 0-0.237), and the posterior probability of infection would be 0.37 (see Appendix B.3).
When sample size (n)/herd size (N) > 0.1, the binomial sampling approximation is no longer appropriate and the hypergeometric distribution, which is based on finite population sampling, should be used for analysis, i.e. x j (P T , Se, Sp) $ hypergeometric(N, n, P A ). The Bayesian Disease Freedom (BDFree) software, which can be downloaded from www.epi.ucdavis.edu/diagnostictests, contains a module for estimating P T under finite population sampling. Assume that in the previous example, all 675 cows in a known infected herd were tested and 23 were ELISA positive (i.e., the apparent prevalence is almost identical to the estimate based on the sample of 60 cows). Using BDFree (see Appendix B.4), P T = 0.025 (95% PI: 0.001-0.152). The posterior probability that the herd is infected given that 23 cows test positive is 0.96.
Computational methods for prevalence estimation are much more complex for finite population sampling than for binomial sampling and we refer readers elsewhere for details (Cameron and Baldock, 1998; Su et al., 2004) .
True versus apparent prevalence
In the context of prevalence estimation, inferences for P T are preferred to inferences for P A . Nevertheless, if test Se and Sp are assumed to be constant and we want to ascertain only if P T is increasing or decreasing over time in a herd, we can make use of the linear relationship resulting from (7); P T = mP A + C where m =1/J and C =(SpÀ1)/J are both constants. Consequently, if P A increases (decreases) we infer that P T increases (decreases). For these conclusions to be valid, the same diagnostic test with constant Se and Sp over time must be used on each occasion and the sampling scheme and cutoff for test interpretation must be unchanged.
4. Individual-level prevalence estimation from pooled samples
Uses of pooled testing: advantages versus disadvantages
Though pooling has been used for detection of fish pathogens in aquaculture for at least 20 years (Worlund and Taylor, 1983) , the use of artificially-created pools for diagnostic testing in livestock species is a recent occurrence (Nielsen et al., 2000; Borel et al., 2004; Tavornpanich et al., 2004; Letellier et al., 2005; Brinkhof et al., 2006) . One pooled sample can be used to determine the pathogen status of a herd (infected or non-infected), while individual-level infection prevalence can be estimated if multiple pools are tested (Cowling et al., 1999; Christensen and Gardner, 2000) . In this section, we focus mainly on issues related to individuallevel prevalence estimation using data from pooled samples.
When sample collection costs are low relative to test cost and P < 0.1 (i.e. the condition is rare) (Sacks et al., 1989; Tu et al., 1994) , pooled testing can be more costeffective than individual testing and can provide more precise prevalence estimates per number of tests used (Kline et al., 1989) . These advantages are based on the assumption that there is no loss of test accuracy resulting from aggregation of samples and that bias is negligible (implies moderate to small pool sizes and large sample sizes). Disadvantages of pooled testing include the need to store and handle larger volumes and the potential for loss of Se and possibly Sp compared with use of individual samples (Christensen and Gardner, 2000) .
Sensitivity and specificity of pooled tests
The pooled sensitivity (PSe) is the probability that a pool will test positive given that it contains at least one sample from an infected animal, while pooled specificity (PSp) is the probability that a pool will test negative given that it does not contain a sample from any infected animal (Munoz-Zanzi et al., 2006) . Although several authors mention the necessity for the 'no loss of test accuracy assumption' (PSe = Se and PSp = Sp), especially as it applies to PSe (Kline et al., 1989; Tu et al., 1995; Cowling et al., 1999; Christensen and Gardner, 2000) , there is a dearth of information in the animal health literature on this topic. It is assumed that PSe depends on the prevalence of the agent, its concentration in infected samples, the number of samples per pool, the mechanism by which the test identifies positivity, and the analytic and diagnostic sensitivity of the assay to be used (Munoz-Zanzi et al., 2006) . For instance, an increase in pool size when testing for bovine viral diarrhea using real-time PCR (Munoz-Zanzi et al., 2006) and when testing for MAP using fecal culture (Wells et al., 2002) has been found to decrease PSe. Others found that PSe was greater, the greater the number of infected samples per pool when testing for MAP using fecal culture (Tavornpanich et al., 2004) . PSp is a function of the degree of cross contamination of the pool by other related agents. Some authors have suggested that larger pool sizes may increase PSp because of dilution of falsepositive-causing analytes (Christensen and Gardner, 2000) . Others (Munoz-Zanzi et al., 2006) have found opposite results and have speculated that larger pool sizes increase the probability of more contaminants being included in the pool. The effect of different factors on PSp is likely to be disease-and test-dependent, and would not apply to bacterial or virus isolation, which should be perfectly specific.
Culture of fecal pools has been the testing method of choice for pooled-sample estimation of MAP infection prevalence at both the individual (Kalis et al., 2000; Wells et al., 2002; Tavornpanich et al., 2004) and herd level (Wells et al., 2003; Kalis et al., 2004) . Compared with individual animal testing for MAP infection, pools of feces from 5-10 animals lead to substantial economic savings with commensurate minor losses in test accuracy (PSe % Se and PSp % Sp). In particular, PSp = Sp when testing for MAP using fecal culture.
Frequentist estimation
Fixed pool size and no available test information
If test Se and Sp information is not available, a simple approach uses the following formula (Kline et al., 1989; Sacks et al., 1989) :
where s p = pool size, x p = number of pools testing positive and n p = total number of pools. An approximate 100(1Àa)% CI for P A is:
where p p = x p /n p (empirical prevalence of positive pools).
Example
Assume that we randomly select 120 cows from a large herd. Fecal samples are obtained from all 120 and pooled into groups of 10. Fecal culture is performed on all pools and five pools test positive for MAP. Using (10) and (11) yields P A = 0.053 (95% CI: 0.007-0.098). Apart from the implicit assumption of perfect Se and Sp, one disadvantage of this method is that for low numbers of positive pools, negative lower confidence limits may result (Cowling et al., 1999) . If in our example, x p = 2, using (10) and (11) 
where q p =1Àp p , for the lower and upper bounds, respectively (Tu et al., 1994 (12) and (13) make use of a continuity correction, bringing continuous normally-distributed variables into closer agreement with the discrete binomial distribution (Fleiss, 1981) . Another alternative is to calculate exact confidence intervals using (4) 
Fixed pool size and imperfect test sensitivity and specificity
If information on Se and Sp is available, the conditions 1ÀSp p p Se and Se + SpÀ1 > 0 must hold in order to estimate P T (Tu et al., 1994) . We assume that PSe = Se and PSp = Sp and if Se and Sp are known, then the following formula can be used to estimate P T :
where J p = PSe + PSpÀ1. An approximate 100(1Àa)% CI for P T is given by (Tu et al., 1994) :
where
If asymptotic assumptions fail, equations (12) and (13) may be used to obtain lower and upper confidence limits for p p , which can then be substituted into (14) for p p to obtain a CI for P T (Tu et al., 1994; Cowling et al., 1999) . Alternatively, exact confidence limits may be calculated for p p and similarly substituted into (14) (Cowling et al., 1999) . The Pooled Prevalence Calculator (PPC) (http://www.ausvet. com.au/pprev/) facilitates easy calculations of both exact and asymptotic CIs for pooled prevalence (see Appendix A.2).
If Se and Sp are not known with certainty, an approximate 100(1Àa)% CI for P T is given by (Cowling et al., 1999) :
C p =PSp(1ÀPSp)=n 2 and n 1 and n 2 (as before) refer to the number of infected and non-infected animals, respectively, used in the original test validation study. Using n 1 = 182 and n 2 = 100 (Sockett et al., 1992) , P T = 0.112 (95% CI: À0.026 to 0.249). The (unrealistic) negative lower confidence limit reflects the increased difficulty in justifying large-sample normal approximations with relatively small sample sizes when test characteristic uncertainty is taken into consideration. Currently, there are no frequentist exact methods that incorporate uncertainty in Se and Sp. Thus, for reasons previously mentioned (see section 3.3.1), we advise against using (16) when prevalence is low.
Bayesian estimation
As pooled testing is most cost-effective when prevalence is low, approaches that incorporate test Se and Sp and provide realistic results (i.e. estimates and limits within the range 0-1) are particularly desirable for those situations. A Bayesian approach ensures that intervals are bounded below by 0. We assume a binomial distribution (Branscum et al., 2004) for the number of pools that test positive and thus x p j(P T , PSe, PSp) $ bin(n, p p ), where
. As in the case of prevalence estimation based on individual samples, beta distributions are chosen to model uncertainty in P T , PSe and PSp, and mixture models can be used to allow for zero prevalence (analogous to the development in section 3.3.2).
Example
Fecal samples from n = 60 cows of a herd of N = 2223 are obtained, randomly aggregated into 6 pools of 10 each and each pool is tested for MAP using fecal culture (Se = 0.60 and Sp = 0.999) (see Table 1 ). Two pools test positive. In a previous testing within other herds in the region, the most frequently occurring prevalence was 0.13 and the herd veterinarian is of the opinion that if MAP is present in this herd, no more than 1 in 4 animals would be infected. The herd is located in a region that has a herd prevalence of MAP infection of 95%. Using BetaBuster, we obtain a P T $ beta(5.87, 33.61) given that the herd is infected. The prior probability that the herd was infected was set equal to 0.95. The results of the Bayesian analysis (see Appendix B.5 for code) were P T = 0.18 (95% PI: 0.08-0.32). Given that 2 of 6 pools test positive, the posterior probability that the herd is infected is 0.997.
Herd prevalence estimation
General concepts
Definition of a herd
A herd is defined as any cluster or grouping of animals (Christensen and Gardner, 2000) , often defined by location (Boelaert et al., 2000; Tavornpanich et al., 2004) but may also be defined by size (Baggesen et al., 1996) , intended purpose (Christensen et al., 2002) , clinical signs (Wells et al., 2003) , age (Boelaert et al., 2000) or combinations of the above. The herd (or herd-level) prevalence (HP) of infection in a population of herds is defined as the proportion of infected herds in the population: HP = number of infected herds=total number of herds in the population (of herds): In contrast to individual-level prevalence surveys, the unit of analysis in herd-level surveys is the herd or whole group.
Herd testing
Herd testing is typically undertaken to classify the status of a herd (or herds) with respect to disease or infection. If the goal is to make statistical inferences regarding HP, then herds to be tested should be selected using a random sampling scheme that is likely to ensure disperse coverage of the targeted region. Typically, a two-stage sampling design is used where M herds are randomly sampled in the first stage and then n i animals are sampled from each herd i, i =1, . . ., M. Selection of animals within herds may be done randomly or not depending on the survey goals (e.g. estimation of within-herd prevalence versus classification of herds by infection status). In the veterinary literature, herd tests and herd-prevalence estimation have been conducted for health certification (Cameron and Baldock, 1998; Kalis et al., 2004) and diagnostic test evaluation (Sergeant et al., 2002; Wells et al., 2003; Tavornpanich et al., 2004) , to identify herdlevel risk factors for individual and herd-level infection (Delafosse et al., 2006) , and for assessments of exposure to etiologic agents (Turnquist et al., 1991) .
Unlike individual-level testing, herd-level testing is a function of two cut-off points: the positivity threshold of the diagnostic test(s) used to classify individual animals as infected or not and the herd cut-off value for classifying herds as infected or not (Christensen and Gardner, 2000) . The herd cut-off value may be an absolute number (e.g. ! 2 infected animals classifies the herd as infected) or a percent (e.g. ! 1% of animals infected classifies the herd as infected).
Herd sensitivity and specificity
Herd-level sensitivity (HSe) is the proportion of infected herds in which the number of animals with positive test results equals or exceeds the herd-level cut-off (Martin et al., 1992) . With the decision rule that uses a cut-off of ! 1 positive test result to classify the herd as positive, HSe =1À(1ÀP A )
n (Christensen and Gardner, 2000) , where n denotes the number of animals tested from the herd. HSe increases with increased n, P A (and hence P T ), and Se and decreases with increased within-herd cut-off for a positive test result (Martin et al., 1992; Donald et al., 1994) .
Herd-level specificity (HSp) is the proportion of noninfected herds that test negative in the population of herds, i.e. the proportion of non-infected herds in which the number of animals with positive test results is less than the within-herd cut-off (Martin et al., 1992) . With a cut-off of 1 for herd infection, HSp = Sp n (Christensen and Gardner, 2000) . HSp increases with increased cut-off values and Sp, and decreases as n increases (Martin et al., 1992; Donald et al., 1994) .
Herd-level test characteristics are also affected by within-herd correlation in disease or infection states (Donald et al., 1994) . For a detailed account of the effect of correlation on herd-level test characteristics, the reader is referred to Donald et al. (1994) .
Frequentist approach
Analogous to individual-level prevalence, true herd-level prevalence is estimated by (Wagner and Salman, 2004) :
where c HP A is the estimated apparent herd prevalence (i.e. number of test-positive herds/total number of herds tested) and J H = HSe + HSpÀ1. An approximate 100(1Àa)% CI for HP T is given by
where n H is the number of herds tested. The application of (17) and (18) to herd prevalence estimation is problematic as it is necessary to assume common values for HSe and HSp. This also implies a common value for P A , which would unrealistically imply constant infection prevalence from herd to herd. As a result, we discourage routine use of these formulas in favor of the Bayesian approach to herd prevalence estimation presented in the next section.
Bayesian approach
In the Bayesian setting with binomial sampling, we model within-herd prevalences as independent and identically distributed according to a common prevalence distribution, and we assume that the test's Se and Sp are invariant from herd to herd. The number of animals that test positive in each herd is modeled as
) with independent beta priors for Se and Sp. As in the single herd setting, each within-herd prevalence is modeled according to a mixture distribution that models zero infection prevalence with probability 1ÀHP T where HP T denotes the herd-level prevalence in the region. For infected herds, the within-herd prevalence distribution is given by P T i $ beta(my, y (1Àm)) where m is the mean true prevalence in the population and y is a parameter related to the variance of the prevalence distribution that flexibly allows for disperse (e.g. uniformly distributed) or very similar infection prevalences among herds (Branscum et al., 2004) . Large values of y indicate less variability so that within-herd prevalences concentrate around m, while small values of y correspond to more heterogeneity of prevalence values across herds (Donald et al., 1994; Branscum et al., 2004) . The mean prevalence (m) and y are typically modeled with beta and gamma distributions, respectively (Hanson et al., 2003a; Branscum et al., 2004) , but other distributions can be used. A Bayesian approach allows not only for herd-level prevalence estimation but also provides a straightforward means to make predictive inferences about herds not tested during the survey. It is also possible to estimate the intracluster correlation coefficient for true prevalence among the study herds (Branscum et al., 2005b) .
Example
Using a two-stage sampling scheme, 29 dairy herds were randomly selected from dairy practices in central California. Random samples of 60 cows were selected from each herd and tested for MAP infection using serum ELISA. Data from the 29 herds are summarized in Table 2 and we assume a binomial distribution for the numbers of animals testing positive. Based on expert opinion, 60% of herds in this region of California were expected to be infected at the time of sampling with a one-sided 95% limit of 30% (i.e. the expert was 95% sure that Frequentist and Bayesian approaches to prevalence estimationthe proportion of MAP-infected herds was greater than 0.30). BetaBuster yields a beta(4.8, 3.6) prior for HP T . The ELISA test Se and Sp are modeled as in previous sections (see Table 1 ). The mean prevalence (m) and y were modeled using beta(3.283, 17.744) and gamma (4.524, 0.387) priors, respectively (see Hanson et al., 2003a , for rationale and method of derivation). Finally, a mixture model was used because some herds in the region might be free of MAP-infected animals. The model was fit using WinBUGS (see Appendix B.6 for code).
The estimated posterior median of HP T was 0.51 with 95% PI from 0.27 to 0.80, while the mean prevalence among infected herds was m = 0.18 (95% PI: 0.08-0.33). The estimated posterior prevalence distribution characterizes the within-herd prevalences in the region. At the time of sampling, 49% of the herds in the region were estimated to be free of MAP infection, 59% of the herds in the region had infection prevalence < 0.05 and 82% had infection prevalence < 0.2.
Comparison of prevalence
Sequential testing in herds
Investigators often sequentially test herds as a means of evaluating the effectiveness of management practices or interventions aimed at controlling or eradicating MAP infection, or to longitudinally monitor changes in infection prevalence. On other occasions, prevalence might be compared between two herds or two groups of animals within herds to determine whether or not they differ. Depending on the goal of the survey, the samples may or may not be regarded as statistically independent.
Frequentist comparison of population prevalence
Independent samples
To determine if two apparent prevalences (P A1 and P A2 ) are statistically different based on test results obtained from random samples of animals from distinct herds, a chi-square (c 2 ) test of homogeneity of proportions may be performed (Agresti, 1996) ;
where both i and j =1, 2, O ij and Ê ij are the observed and (estimated) expected values, respectively, in the ith row and jth column of a 2·2 contingency table (see Table 3 ) andP A 1 =n 11 =n +1 andP A 2 =n 12 =n +2 . The estimated expected value is Ê ij = r i c j /n, where r i and c j are the ith row and jth column totals, respectively. The statistical hypothesis to be tested is: H 0 : P A1 =P A2 versus H 1 : P A 1 ÞP A 2 with degrees of freedom (df)=(RÀ1) (CÀ1) = 1, where R and C are the number of rows and columns, respectively (R = C = 2 for 2·2 tables). The null hypothesis (H 0 ) is rejected if c 2 > c 2 df = 1,1Àa where c 2 df = 1,1Àa is the value corresponding to the 1Àa percentile of the c 1 2 distribution and a = type I error probability.
Example
Assume that 1 year after an initial testing, the herd described in section 3.1.1 is again tested for MAP, and 30/200 cows have positive test results, yielding an apparent prevalence (P A2 )=0:15 (Table 3 ). To test whether P A 2 and P A 1 are statistically different, we use (19) and a = 0.05. This yields c 2 = 0.33 < c 2 1,0.95 = 3.84, hence we do not reject H 0 (i.e., there is no statistical evidence suggesting a change in apparent prevalence). A 100(1Àa)% CI for P A2 ÀP A1 is
Hence,P A 2 ÀP A 1 =0:02 with 95% CI of À0.05 to 0.09. For statistically independent samples, if any Ê ij < 5, the Fisher exact test is recommended to compare independent proportions (Rosner, 2000) .
Dependent samples
In the previous example, if on both occasions the same cows were sampled (matched pair or repeated measures design), the data may be presented as in Table 4 and a McNemar's c 2 test of homogeneity of proportions that accounts for correlated data should be performed. Here, (Agresti, 1996) c 2 =(n 12 Àn 21 ) 2 =(n 12 +n 21 ),
where n 12 and n 21 are the numbers of cows with discordant test results (T + TÀ and TÀT + , respectively) at the initial and subsequent sampling. If n 12 Þ n 21 then P A 1 ÞP A 2 and (21) 
where p ij = n ij /n p , p 1 + =p 11 +p 12 , p + 1 =p 11 +p 21 and n p refers to the number of cows (each tested twice). Hence, if the same cows were tested on both occasions, the With data subject to misclassification (i.e. Se and Sp both < 1), there is no straightforward frequentist method for testing differences between true prevalences. However an informal test of the difference between two true prevalences may be performed by checking for overlap of their individual CIs with adjustments made for multiple comparisons since a collection of separate 100(1Àa)% CIs may have joint confidence less than 100(1Àa)%. Overall, caution should be exercised when applying this conservative procedure to Wald CIs. Compared with standard hypothesis testing, the method both rejects the null hypothesis less often when it is true, and fails to reject the null more frequently when it is false (Schenker and Gentleman, 2001 ).
Bayesian comparison of population prevalence
Using a Bayesian approach, inferences can be made for differences in true prevalences between two (or more) true population prevalences. Assuming independent binomial sampling and that both herds (section 6.2.1) were tested for MAP infection using the same serum ELISA (Table 1 ), a Bayesian model for the data is x j j(P Tj ,Se,Sp) $ Bin(n j ,P Aj ) where P Aj =P Tj Se+ (1ÀP Tj )(1ÀSp) for j = 1, 2 and beta priors are used for P Tj , Se and Sp. We require informative priors for Se and Sp to mitigate lack of identifiability (i.e. ensure that prevalences are estimable). Here, based only on the data, x j /n j estimates P A j and we require additional input about test accuracy to estimate true prevalence. With the data and expert-elicited information about Se and Sp, inferences for P T2 ÀP T1 can be made.
Example
Assume that based on the presence of culture-confirmed clinical cases of Johne's disease, both herds are known to be infected with MAP. Suppose, however, that no records of previous test results are available and, hence, the magnitude of within-herd prevalence of MAP infection is unknown. We thus use uniform priors for P T2 and P T1 (P T2 ,P T1 $ beta (1,1) ). The ELISA Se and Sp are modeled as in previous sections (Table 1) , and the model is fit in WinBUGS (see Appendix B.7 for code). The posterior median of P T 2 ÀP T 1 is 0.08 with 95% PI from À0.24 to 0.44. On the basis of the posterior probability, Pr(P T2 > P T1 jdata)=0:71, we are 71% certain that herd 2 has a higher true prevalence than herd 1.
A Bayesian approach also facilitates comparisons of prevalence when different diagnostic tests are used in the two herds. For example, if herd 2 was tested with fecal culture and Se and Sp are modeled as in previous sections (see Appendix B.8 for code), the posterior median of P T 2 ÀP T 1 is À0.09 with 95% PI from À0.62 to 0.29. Given that the posterior probability Pr(P T 2 >P T 1 jdata)=0:31, we are 31% certain that herd 2 has a higher true prevalence than herd 1 (P T1 =0:38 (95% PI: 0:14--0:90) and P T 2 =0:28 (95% PI: 0:16À0:60)).
Reporting of results
For presentation of results based on frequentist or
Bayesian analysis of prevalence data based on hypothesis tests, we encourage the use of interval estimates (e.g. 95% CIs or PIs) rather than, or in conjunction with, P-values or posterior probabilities. Whereas CIs and PIs help to reveal whether different statistically significant (or insignificant) results have different implications for policy or intervention decisions, P-values, which reduce results into a significant-non-significant dichotomy, obscure quantitative differences between results.
Sample size and power
Relevance of sample size estimation
A critical aspect of the planning phase of a prevalence survey is the estimation of the number of individuals or groups of individuals needed. The sample size determines the precision of our final estimates and ultimately influences whether the survey will be able to address the research questions of interest. Limited time and resources dictate that prior to performing a study, an investigator should be reasonably assured that enough individuals are available so that estimates can be generated with the requisite precision. Consequently, sample size calculations are standard requirements for research grant proposals. Because the components of these calculations must be hypothesized, only estimates can be obtained for any proposed study. This uncertainty becomes more pronounced in prevalence surveys when accuracy of case identification and precision of estimates is also dependent on diagnostic test characteristics. Bayesian approaches to sample size calculations for prevalence surveys account for uncertainty in parameter values (e.g. for Se and Sp) and for data subject to misclassification. As a result, they n p = the total number of pairs.
Frequentist and Bayesian approaches to prevalence estimationare computationally intensive and cannot be directly implemented in WinBUGS (see, for example, Johnson et al., 2004; Branscum et al., 2006) . For this reason, we present only methods for frequentist sample size calculations in this section and point the interested reader to other sources covering the general methodology for Bayesian sample size determination (Adcock, 1997; Rahme et al., 2000) .
Sample size required to estimate true and apparent prevalence with a given precision
Precision of an estimate may be defined as the width of its (100Àa)% CI. The sample size necessary for estimating P A and P T , respectively, within a given error margin (D) is given by (Greiner and Gardner, 2000b) :
and (Greiner and Gardner, 2000a) n=
respectively, where _ P A is an a priori estimate of P A (for example, obtained via pilot surveys or expert opinion) and D = half the CI width, which may be either an absolute number or a percentage of _ P A (or _ P T ). Table 5 provides estimates of the number of cows necessary for testing to estimate P T for MAP infection when D ranges from 0.10 to 0.20, given a priori estimates of P A for testing with serum ELISA (Se = 0.30, Sp = 0.96) and fecal culture (Se = 0.60, Sp = 0.999) and assuming that the test characteristics are known. For fixed _ P T ( _ P A ), as D increases (decreases), the required sample size decreases (increases), while for fixed D, as Se and/or Sp increase (decrease), the required sample size decreases (increases). Thus, the sample size required to estimate P T (P A ) will be inversely proportional to the desired precision. If Se and Sp are not assumed to be known, then (24) can be generalized to adjust for uncertainty in Se and Sp using (Greiner and Gardner, 2000a) n=
where B = Se(1ÀSe)/n 1 , C = Sp(1ÀSp)/n 2 , and n 1 and n 2 are as previously defined for (9).
Sample size to detect a difference in prevalence
Sample size calculations to detect prevalence differences have four fundamental components: the significance level or the probability of falsely concluding that there is a difference when none exists (a = probability of type I error), the probability of falsely concluding that there is no difference when there is one (b = probability of type II error), the variance of the parameter to be estimated and, most critically, the size of the parameter itself, i.e. the difference to be detected (Wittes, 2002) .
Independent random samples
To calculate the sample size (n s = n 1 + n 2 ) necessary to detect a difference P A 1 ÀP A 2 from two independent random samples, we use (Rosner, 2000) :
and n 2 is computed based on k = n 2 /n 1 where k is usually determined by the investigator. Here,
A two-tailed hypothesis test is implied by (26), i.e., H 0 : P A1 =P A2 versus H 1 : P A 1 ÞP A 2 . Common choices of a and 1Àb are 0.05 and 0.8, respectively, and total sample size (n s ) is minimized for k =1 (n 1 = n 2 ). To estimate sample sizes based on one-tailed hypotheses (to identify either an increase or decrease in P A ), z a/2 is substituted with z a in (26). However, if the inherently two-tailed c 2 statistic is to be used to test differences in prevalences, then the sample size estimation must be two-tailed to avoid sample size underestimation. One-tailed sample size calculations should be performed only if a one-tailed test is to be used to determine a difference in prevalence during data analysis (Lachin, 1981) .
7.3.1.1. Example Assume that two large herds have prevalences of MAP infection of _ P A 1 =0:10 and _ P A 2 =0:15. We wish to determine if jP A2 ÀP A1 j ! 0:05. We therefore calculate the required number of animals to sample in order to have a probability of 0.8 of detecting jP A 2 ÀP A 1 j=0:05 if such a difference exists. Using a = 0.05 and 1Àb = 0.8 and Table 5 . Sample sizes to estimate hypothesized true prevalences (Ṗ T ) with a given precision (D) based on a priori apparent prevalence estimates (Ṗ A ) for serum ELISA and fecal culture assuming known sensitivity (Se) and specificity (Sp) assuming that equal numbers of animals (k = 1, i.e. n 2 = n 1 ) are available to randomly sample, (26) yields n 1 = 685 and sample size (n s ) = 1370. Sometimes sample sizes need to be calculated to detect a change in test prevalence of MAP infection between two time points in a single herd. Sampling at the first time point may already have occurred when the need for the sample size calculation arises and economic considerations may influence whether the same number of cows can be tested at the second sampling.
Example
Assume that we have a very large herd. In an earlier random sample of 600 cows, 60 tested positive, i.e., P A1 = 0:10. New management practices were introduced to reduce the prevalence of MAP infection and, 1 year later, we wanted to evaluate if the apparent prevalence has decreased by 5% P A2 = 0:05 ð Þ . Costs of testing have increased and total costs would be reduced if testing less than 600 animals were possible. First, we need to calculate the ratio of numbers of animals necessary to sample in order to have a probability of 0.8 of detecting this difference (0.05) in prevalence if it exists. Using a = 0.05 and 1Àb = 0.8 and assuming that equal numbers of animals are available to sample (randomly), the implied one-sided hypotheses are H 0 : P A1 =P A2 versus H 1 : P A1 >P A2 (Roussas 2003) . We assume for simplicity that the data are statistically independent because of the time between the two sampling dates.
We first calculate the total sample size as if equal sized samples (i.e. n 2 = n 1 ) were to be used, denoted n s(k = 1) , using z a = 0.05 (one-sided hypothesis) in (26). This yields n s(k = 1) = 684. We then make use of the following relationships (Altman, 1991) :
From (27) and (28), n 1 = n s(k = 1) (1 + k)/4k. Since 600 animals have already been sampled, we let n 1 = 600 and n s(k = 1) = 684 (from above). This yields k % 0.398 and n 2 = 239. Hence, we sample 239 cows at the second sampling and 839 cows in total.
Dependent samples
The number of paired observations (n p ) necessary to detect a difference in P A estimated from testing each cow at two different time points is given by (Lachin, 1992) :
where ṗ 12 and ṗ 21 are the a priori probabilities that a cow will have test results T + TÀ and TÀT + , respectively, at the two testing times (see Table 1 , Appendix A.4). In the context of a group of animals tested at two time points, n p refers to the number of pairs of tests to be done (i.e. the number of animals to be tested).
Example
Assume that we have a large herd known to be infected with MAP. We wish to determine if the prevalence of infection is increasing in the herd and thus plan to select a group of cows and test them longitudinally at two time points. We assume based on previous experience with other herds and with the diagnostic test to be used that $ 87% of cows tested will have the same test result at both testings. In addition, we assume that P A 1 ( _ p 1+ )=0:05 and P A 2 ( _ p 2+ )=0:10, respectively (see Appendix A.4). Hence ṗ 12 + ṗ 21 = 0.13 and ṗ 21 Àṗ 12 = 0.05. Using a = 0.05, z a (onesided hypothesis) and 1Àb = 0.8, from (30), n p % 318 pairs of tests (318 cows).
Sample size based on true prevalence
Sample sizes to detect differences in P T are done by first determining the difference in P T that is important to identify. The Rogan-Gladen estimator (7) is used to calculate the equivalent difference on the P A scale and then equation (26) or (30) is used to find the sample size necessary to detect the difference on the P A scale. We recommend that sample size estimation be done based on true rather than apparent prevalence estimates (see Table 6 ), wherever possible. 7.5. Sample size required to estimate individual-level prevalence from pooled samples Formulas for numbers of pools required to estimate individual level true and apparent prevalence can easily be derived given corresponding variance formulas (Tu et al., 1994; Cowling et al., 1999) . For fixed pool sizes, the formula for number of pools necessary to estimate P A within a given error margin (D) is
If an a priori estimate is given of the prevalence of positive pools (ṗ p ), then:
Given an a priori estimate of true prevalence, when Se and Sp are assumed known
If Se and Sp are not known,
C p = PSp(1-PSp)/n 2 and n 1 and n 2 (as before) refer to the number of infected and non-infected animals, respectively, used in the original test validation study. As in the case of individual samples, D may either be a constant or a percentage of the prevalence to be estimated. Comparing pool sizes of 5 and 10, we note that for a given a priori P A (or P T ), PSe, PSp and D, pool sizes of 10 require overall fewer individual samples (see Table 7 ).
Sample size required to estimate herd prevalence
Sample size calculations for estimation of herd prevalence have both within-herd and among-herd components. Determination of the sample size to detect infection is an important first step in correctly determining the MAP infection status of each herd. In the context of a herd prevalence survey of M herds (h 1 , h 2 , . . ., h M ) the number of samples required to detect at least one truly infected animal in the ith herd (h i ) (where i M), assuming binomial sampling, is given by (Christensen and Gardner, 2000) :
where C is the level of confidence (e.g. 95%) in detecting at least 1 truly infected animal (i.e. HSe) given an a priori specified true prevalence for that herd _ P T i À Á and Se i and Sp i are the test's sensitivity and specificity in that herd respectively. Because herd-specific values of Se i and Sp i are not usually known, sensitivities and specificities are usually assumed to be invariant across herds. Thus the required sample size for each herd is a function of true prevalence, the desired confidence and the diagnostic test's Se and Sp. The total number of animals necessary to sample in order to have a confidence C to detect at least 1 infected animal in each herd is given by:
Corrections to (35) and (36) can be made for finite population sampling (see, for example, Martin et al., 1992) . If within-herd prevalence estimates are not required, after initial sample size calculation using (36) above, risk-based (targeted) sampling may be used to select animals with a greater likelihood of being infected for testing if prior knowledge of risk factors for infection (e.g. previous diagnostic test results, clinical signs, etc.) is available (Christensen and Gardner, 2000) . For a given sample size, risk-based sampling increases the confidence to detect at least one infected animal in a herd when compared with random sampling. This has been substantiated by results from a number of studies (Nielsen et al., 2002a; Tavornpanich et al., 2006) . Conversely, risk-based sampling can be used to reduce the sample size necessary to achieve a herd diagnosis for fixed confidence level.
The number of herds required to estimate true herd prevalence (HP T ), within a given error margin (D) is Table 6 . Sample sizes (numbers in each group) 1 required to detect differences in true prevalence (P T ) for independent samples (a = 0.05, 1Àb = 0.80 and k =1(n 2 = n 1 )) Serum ELISA (Se = 0.3, Sp = 0.96) Fecal culture (Se = 0.6, Sp = 0.999) given by (Humphry et al., 2004) :
where n H = the estimated number of herds, W = Hse(H _ P T ), P =(1ÀHSp)(1ÀH _ P T ), D = prescribed error margin, J H = HSe + HSpÀ1 and z a/2 as before, refers to the 1Àa/2 percentile of the standard normal distribution. The test's HSe and HSp are both pre-specified by the investigator and therefore assumed known without error. Table 8 provides estimates of the number of herds required to estimate HP T = 0.7 and 0.9, respectively, within an error margin (D) = 0.1 with 95% confidence.
Sample size required to substantiate freedom from infection
Strictly speaking, to unequivocally demonstrate freedom from MAP infection in a herd or in a group of herds from a well-defined geographical region, all animals should be tested using a perfect test. However, a sample may be used to establish with prescribed probability that infection, if present, is below a predetermined level, i.e. a certain minimum expected prevalence (also known as design prevalence). For a herd, the minimum expected prevalence of infection would be the minimum prevalence expected if infection were actually present (Cameron and Baldock, 1998 ). This prevalence estimate should be based on knowledge of the disease and its risk factors, knowledge of the herd itself (including previous results of surveillance and disease-related interventions) and knowledge of the Se and Sp of the diagnostic test to be used. At the regional level, the minimum accepted herd prevalence would be the lowest (non-zero) unacceptable herd prevalence, based on economic or political factors (Cameron and Baldock, 1998) . For substantiation of freedom from infection, two-stage sampling is usually employed. Sample sizes for both herd-level and within-herd testing to establish that infection is below a specified prevalence in a given region may be estimated using the 'Freedom from Disease' drop-down menu within the 'Survey Toolbox' or 'FreeCalc', which are both available at www.vetschools.co.uk/ EpiVetNet/Sampling_software.htm (see Appendix A.5).
Example
Assume that in a region with 1000 dairy herds (herd sizes of 500-1500 cows) where the herd prevalence of MAP infection was initially 90%, substantial eradication efforts are undertaken and it is now claimed that the herd prevalence is below 50%. Veterinary authorities expect that, within any given herd, 2% or more of the animals will be infected if MAP is present. Fecal culture (Se = 0.60, Sp = 0.999) is to be used for testing. Using the modified hypergeometric exact formula within the Survey Tool Box with HSe = 0.95 and HSp = 0.98, and 95% confidence and power, we calculate that if 8 herds are chosen randomly and 1 herd tests positive, we can be $ 95% confident that HP T < 0.5 (see i-iv, appendix A.5). The Survey Tool Box also calculates the numbers of animals necessary to sample (based on herd sizes) in order to be $ 95% certain that infection, if present, is 2%, given type I (1-HSe) and type II (1-HSp) errors of 0.05 and 0.02, respectively (see v-viii, appendix A.5). The survey would then be conducted by randomly sampling 8 herds and then choosing random samples of between 402 and 455 cows from herds of between 500 and 1500 respectively. If > 2 animals test positive for MAP in at least 2 of the 8 herds, then the survey has not provided evidence that HP T < 0.5. However, if either 0 or 1 herd has > 2 animals testing positive, then we can conclude with more than 95% confidence that the true herd prevalence (HP T ) of MAP infection in the region is < 0.5 and where present, the true individual-level prevalence (P T ) of MAP infection is < 0.02.
For a given herd, the lower the minimum expected prevalence and the more inaccurate the diagnostic test, the greater the sample size necessary to substantiate freedom from infection (Cameron and Baldock, 1998) . Given a herd of 1000 cows and that diagnostic testing is to be done using fecal culture (Se = 0.60 and Sp = 0.999) or ELISA (Se = 0.30 and Sp = 0.96), Table 9 provides sample size estimates and maximal numbers of animals testing positive in order to establish with 95% confidence Table 8 . Number of herds required to estimate hypothesized true herd prevalences of 0.7 (HṖ T = 0.7) and 0.9 (HṖ T = 0.9) with precision (D = 0.1) and 95% confidence (z a/2 = 1.96) for different combinations of herd sensitivity (HSe) and herd specificity (HSp) HSe HSp (HṖ T = 0.7)
HSp (HṖ T = 0.9) (HSe) and 98% power (HSp) that MAP infection, if present, is below a given true prevalence. Bayesian approaches to sample size determination for single herd and regional disease freedom surveys have also been developed (see, for example, Johnson et al., 2004; Branscum et al., 2006) . However, computationallycomplex simulation-based approaches are needed for their implementation and thus we do not present them here.
Power calculations
Relevance of power calculations
In the context of detecting differences in prevalences, power (1Àb) is the probability that the results of the study will be statistically significant given a specified difference between groups (Goodman and Berlin, 1994) . Consequently, power is of direct relevance in the design phase of a study, as a means of determining the likelihood of ultimately detecting a true difference between prevalences given constraints on sample size (due to cost, availability of subjects or other factors). Post-hoc power calculations, though often performed by researchers, are of limited value in both study interpretation and evidence-based decisionmaking. Instead, CIs should be used to evaluate the extent to which the differences (in prevalence) are or are not compatible with the data (Goodman and Berlin, 1994) .
Power estimation (statistically independent samples)
From (26), the power to detect a difference jP A 2 ÀP A 1 j using a two-sided test is given by (Rosner, 2000) :
where n 1 , k, _ P A1 , _ P A2 , _ Q A1 , _ Q A2 _ P A , _ Q A and z a=2 are as defined in section 7.3.1 and F(x) denotes the standard normal cumulative distribution function evaluated at x. 7.8.2.1. Example Assume, as in the second example of section 7.3.1, that having previously sampled 600 cowsP A 1 =0:10 À Á , we wish to detect a possible decrease in prevalence of MAP infection of 5% at a subsequent sampling i.e., P A2 =0:05. However, funding dictates that only 160 cows can be tested. Thus, we estimate the probability of detecting this difference in prevalence, if it exists. Using a = 0.05 and k = 0.267, power=F(0.395) = 0.65. If 160 cows are sampled, there is a probability of 0.65 of detecting a change of 0.05 in apparent prevalence. If we were to sample 240 animals (k = 0.398), power = 0.80.
Power calculations (statistically dependent samples)
From (30), with matched pairs or repeated measures data, the power to detect a difference jP A2 ÀP A1 j is given by: 
where n p , p 12 , p 21 and z a/2 are as defined in section 7.3.2.
Example
Assume that for the herd described in section 7.3.2, testing costs dictate that only 540 tests can be performed (270 animals). Using the information in section 7.3.2 with n p % 270, from (39) F(Z b ) = 0.64 and power = 0.74. Hence, there is a 74% chance of detecting an increase in apparent prevalence of 0.05, if it occurred. 
Conclusion
Frequentist approaches to true prevalence estimation are easy to use but suffer from serious statistical limitations when prevalence is low, sample sizes are small and uncertainty in Se and Sp is to be incorporated into the precision of estimates. These limitations are easily overcome in a Bayesian context and we recommend that investigators use Bayesian methods for prevalence estimation, wherever appropriate.
